Anavar 10 - Canada Peptides

Created by G.D. Searle & Co. in 1962, Oxandrolone emerged as a steroid with high therapeutic potential and low virilization risk. Known commercially as Anavar, it found use in clinical settings for treating conditions like cachexia and developmental delay. It spread globally but was removed from the market in 1989 amidst growing concern about performance-enhancing drugs. The compound was revived in 1995 as Oxandrin by Bio-Technology General Corp., targeting rare diseases and benefiting from orphan drug protections that ensured its availability for critical patient groups.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Anavar 10 by Canada Peptides, consult with your doctor or healthcare professional.